期刊文献+

罗格列酮油水分配系数的测定 被引量:5

Determination of Oil-water Partition Coefficients of Rosiglitazone
原文传递
导出
摘要 目的:采用2种不同方法测定不同pH值下的罗格列酮油水分配系数(logP)。方法:以正辛醇-水为模拟系统,采用摇瓶-紫外分光光度法,测定在不同pH值(0.95、2.0、3.0、4.0、5.07、5.7、6.55、7.06、7.5、8.15、9.21)下罗格列酮在水相和有机相中的药物浓度以计算logP值,并与采用计算机Pallas软件得到的logP预测值比较。结果:当pH<4时,罗格列酮的logP<1;当pH为5~9时,罗格列酮的logP>1。实际测定值与Pallas软件预测的logP值随pH变化趋势相一致。结论:罗格列酮在pH<3时以酸式盐的形式存在,水溶性较好;而在pH5~9时以游离碱形式存在,脂溶性较好。Pallas软件可用于预测药物的logP值。 OBJECTIVE: To determine the oil-water partition coefficients (logP) ofrosiglitazone at different pH values by two kinds of methods. METHODS: A shake flask-ultraviolet spectrophotometry method was used to determine plasma concentration of rosiglitazone in water phase and organic phase at variable pH values (0.95, 2.0, 3.0, 4.0, 5.07, 5.7, 6.55, 7.06, 7.5, 8.15, 9.21) to calculate logP by using with n-caprylic alcohol-water as simulation system. Above logP values were compared with that calculated by Pallas software. RESULTS: The logP value was lower than 1 when pH value was lower than 4; the logP value was higher than 1 when pH value was ranged from 5 to 9. Measured logP values were in good agreement with that calculated by Pallas software. CONCLUSION: Rosiglitazone exists in the form of hydrochloride salt with good water solubility (pH〈3) while it exists in the form of molecule with sound liposolubility (pH 5-9). Pallas software is suitable for predicting the logP value.
出处 《中国药房》 CAS CSCD 北大核心 2010年第5期409-411,共3页 China Pharmacy
基金 重庆市自然科学基金资助项目(CSTC2006BB5286)
关键词 罗格列酮 油水分配系数 Pallas软件 Rosiglitazone Oil-water partition coefficients Pallas software
  • 相关文献

参考文献9

  • 1Sahi J, Black CB, Hamilton GA, et al.Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition[J]. Drug Metab Dispos, 2003,31 (4) :439.
  • 2Theocharis S, Margeli A, Vielh P, et al.Peroxisome proliferator-activeated receptor-γ ligands as cell-cycle modulators[J].Cancer Treat Rev, 2004,30 (6) : 545.
  • 3Fuchtenbusch M, Standl E, Schatz H.Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus[J].Exp Clin Endoerinol Diabetes, 2000, 108(3) : 151.
  • 4Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings[J]. A dv Drug Deliv Rev, 2001,46 ( 1-3) : 3.
  • 5Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability[J]. Bioorg Med Chem Lett, 2009,19 (10) : 2 844.
  • 6吴禄春,甘勇军,方大树,王施韦,胡湘南.利用紫外分光光度法测定罗格列酮游离碱的pKa值[J].重庆医科大学学报,2009,34(11):1546-1548. 被引量:5
  • 7甘勇军,吴禄春,方大树,胡湘南,秦黄英,黄波.罗格列酮钠肠溶片的制备及质量控制[J].中国药房,2009,20(10):773-774. 被引量:3
  • 8甘勇军,吴禄春,方大树,胡湘南.罗格列酮钠肠溶片的体外释放特性[J].中国医院药学杂志,2009,29(14):1159-1161. 被引量:5
  • 9Raskin P, Rendell M, Riddle MC, et al.A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin treated type 2 diabetes[J].Diabetes Care, 2001,24(7) : 1 226.

二级参考文献12

  • 1胡湘南,范博.紫外分光光度法测定西地那非的电离平衡常数[J].中国药房,2006,17(2):134-136. 被引量:5
  • 2史海雯.罗格列酮非降糖作用的研究进展[J].中国药房,2006,17(11):861-863. 被引量:3
  • 3张宇喆,吕竹芬,谢清春,申楼.罗格列酮缓释片释放度测定方法的研究[J].药品评价,2006,3(6):418-421. 被引量:2
  • 4李松.噻唑烷类衍生物及其医药用途[P].中国专利:CN1183130.2005-01-05.
  • 5胡湘南.噻唑烷二酮金属盐类药物肠溶制剂及其制备方法[P].中国专利:CN101327198.2008-12-24.
  • 6Meier C, Kraenzlin M E, Bodmer M, et al. Use of thiazolidinediones and fracture risk[J]. Arch Intern Med, 2008,168 : 820-825.
  • 7Yihong W, Ling W C,Evans Ronald M. PPAR- γ regulates osteoclastogenesis in mice[J]. Nature Medicine, 2007,13 (12) : 1496-1503.
  • 8杭州大学化学分析教研室.分析化学手册[M].第2版.北京:化学工业出版社,1997.335-349.
  • 9重庆医科大学.噻唑烷二酮金属盐类药物肠溶制剂及其制备方法[P].中国发明专利.申请号:200810070013.02008.
  • 10中国药典.二部[S].2005.附录:29.

共引文献8

同被引文献26

引证文献5

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部